Sonesitatug vedotin is a potential new SOC in select Claudin 18.2–positive gastroesophageal carcinoma.
Related to this article
The FDA approved dostarlimab in rectal cancer and pembrolizumab in tumors with high mutational burden, Europe cleared teclistamab in myeloma, and more.
Surufatinib plus serplulimab and cisplatin/etoposide produced a 69.8% ORR in advanced extrapulmonary neuroendocrine carcinoma.
Arcotatug tavatecan improved PFS and OS vs physician’s choice in previously treated, CLDN18.2-positive advanced gastric and GEJ cancer.
Overall survival benefit of daraxonrasib vs chemotherapy extends across RAS genotypes, chemotherapy regimens, and prior treatment settings.
Advertisement
Advertisement
Trending on OncLive
1
Broadening HER2-Mutated NSCLC Data Support First-Line Zongertinib Followed by T-DXd
2
How Allergists Fit Into the Systemic Mastocytosis Management Equation
3
Thorough Treatment Adherence and Selection Anchor Proper TKI Utilization in CML
4